Cerillion PLC (CER)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 700.00 |
|---|---|
| 52-week range | 650.00 – 1,770.00 |
| Return, 1 month / 3 months | +1.2% / −31.4% |
| Return, 1 year / 3 years | −51.5% / −37.3% |
| Trend | Below its 200-day average |
| RSI (14) | 43 |
| Volatility (1 year) | 42.8% |
| Worst drawdown (1 year) | -62.1% |
| Average daily value traded | 141.41M GBX |
| Dividend yield | 2.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Cerillion is a software company that supplies billing, charging and customer management systems to communications providers such as telecom operators and media businesses. Its products handle subscriber billing, revenue management and customer care, helping service providers run their commercial operations. The company is based in London and works with clients in markets around the world, delivering both software licences and related implementation and support services.
Cerillion PLC trades under the code CER on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Cerillion PLC (CER) trades on the London Exchange in UK. It last closed at GBX 700.00 on 23 October 2026.
Its price-based Market X-Ray is 29 out of 100 (a weak price profile), ranking 3,132 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 51.5% and over the last three months it fell 31.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 5 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -40.2% | ||
| From 52-week high | -60.0% | ||
| Momentum | 5 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -31.4% | ||
| 6-month return | -46.9% | ||
| 12-month return, skipping the last month | -52.0% | ||
| Stability (higher is calmer) | 24 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 42.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -62.1% | ||
| Liquidity | 91 · Strong | Trades actively. | |
| Average daily value traded | 141.41M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 62 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.3% | ||
| Years with dividends | 6 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +2.6% |
|---|---|
| 1 month | +1.2% |
| 3 months | −31.4% |
| 6 months | −46.9% |
| 1 year | −51.5% |
| 3 years | −37.3% |
| 5 years | −8.7% |
Signals
| 50-day / 200-day average | 799.46 / 1,171.10 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 35.87 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 11 Jun 2026 | GBP 0.0550 |
| 15 Jan 2026 | GBP 0.1060 |
| 29 May 2025 | GBP 0.0480 |
| 16 Jan 2025 | GBP 0.0920 |
| 24 Dec 2024 | GBP 0.0920 |
| 28 Nov 2024 | GBP 0.0920 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.